Could tofacitinib, the first oral small-molecule inhibitor proven for use in active rheumatoid arthritis (RA) patients with insufficient response to methotrexate, be the breakthrough drug for RA?

Detalles Bibliográficos
Autor principal: Kwok, Seung-Ki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association of Internal Medicine 2014
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164720/
https://www.ncbi.nlm.nih.gov/pubmed/25228832
http://dx.doi.org/10.3904/kjim.2014.29.5.577

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164720/
https://www.ncbi.nlm.nih.gov/pubmed/25228832
http://dx.doi.org/10.3904/kjim.2014.29.5.577

Ejemplares similares